Rockefeller Capital Management L.P. lowered its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 94.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 275 shares of the company’s stock after selling 4,630 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in VanEck Pharmaceutical ETF were worth $28,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. AlphaCore Capital LLC purchased a new stake in shares of VanEck Pharmaceutical ETF in the fourth quarter valued at approximately $31,000. Group One Trading LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the 4th quarter valued at approximately $36,000. EFG International AG purchased a new position in shares of VanEck Pharmaceutical ETF during the 4th quarter valued at approximately $44,000. IFP Advisors Inc lifted its position in shares of VanEck Pharmaceutical ETF by 53.7% during the 3rd quarter. IFP Advisors Inc now owns 438 shares of the company’s stock valued at $40,000 after buying an additional 153 shares in the last quarter. Finally, Birchwood Financial Partners Inc. acquired a new stake in VanEck Pharmaceutical ETF in the 4th quarter valued at $45,000.
VanEck Pharmaceutical ETF Stock Performance
Shares of NASDAQ PPH opened at $108.82 on Tuesday. The firm has a market cap of $934.76 million, a PE ratio of 20.21 and a beta of 0.46. The firm has a fifty day moving average of $105.14 and a 200 day moving average of $105.33. VanEck Pharmaceutical ETF has a one year low of $81.74 and a one year high of $112.58.
VanEck Pharmaceutical ETF Cuts Dividend
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Read More
- Five stocks we like better than VanEck Pharmaceutical ETF
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
